Items Tagged ‘Prostate Cancer’

October 3rd, 2016

Different Treatment Options Appear Equally Effective in Early Prostate Cancer

By

Among men with early prostate cancer that is detected through prostate-specific antigen (PSA) testing, treatment with either surgery, radiation therapy, or monitoring until progression all appear to provide approximately the same survival rates at 10 years. Spread of cancer, however, was higher among those whose cancer was monitored until progression. These results were recently published […]

View full entry

Tags: active monitoring, early, Early Stage I-II (A-B) Prostate Cancer, News, Prostate Cancer, prostatectomy, PSA, radiation, regimen, surgery


August 15th, 2016

Midlife PSA Levels Correlate to Risk of Future Lethal Prostate Cancer

By

A baseline prostate-specific antigen (PSA) level among men at midlife appears to be highly correlated with the risk of developing lethal prostate cancer within their lifetimes. These results were recently published in the Journal of Clinical Oncology. Prostate cancer is the second leading cause of cancer-related deaths among men in the United States. Recently, screening […]

View full entry

Tags: News, Prostate Cancer, PSA, risk, screening, Screening/Prevention Prostate Cancer


August 10th, 2016

New Tool Helps Men Evaluate Watchful Waiting in Early Stage Prostate Cancer

By

Over 90 percent of prostate cancers are detected at a curable stage, with men more likely to die of other diseases than from this cancer. Although patients with localized, low-risk prostate cancer have treatment options: active surveillance, also called watchful waiting, in which the cancer is monitored periodically to detect any changes, or active treatment […]

View full entry

Tags: Decision Counseling Program, News, pilot study, Prostate Cancer, watchful waiting


July 26th, 2016

Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer

By

In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published in the Journal of Clinical Oncology. Prostate cancer is the second leading cause of cancer-related deaths among men in the United States.  Metastatic prostate cancer refers […]

View full entry

Tags: cabozantinib, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer


June 13th, 2016

FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer

By

The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used in positron emission tomography (PET) imaging for the detection of recurrent prostate cancer. Prostate cancer is the second leading cause of cancer-related deaths among men in the United States. If prostate cancer recurs following initial […]

View full entry

Tags: Axumin, fluciclovine F 18, imaging, News, PET, Prostate Cancer, recurrence, Refactory/Recurrent Prostate Cancer, scan


May 25th, 2016

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk

By

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its expansion into the oncology market, with a focus on advancing cancer risk screening and helping cancer prevention efforts. Counsyl’s […]

View full entry

Tags: asco, ASCO16, ASCO2016, BRCAtesting, breast, Breast Cancer, breastcancerawareness, colon, Colon Cancer, DNAtesting, genetic testing, inherited cancer screen


May 18th, 2016

Addition of Radiation Improves Survival in High-Risk Prostate Cancer

By

The addition of radiation therapy to androgen-deprivation therapy among men with prostate cancer who are at a high risk of a cancer recurrence significantly improves long-term survival. These results were recently published in the journal of European Urology. Prostate cancer is the most frequently diagnosed cancer in men aside from skin cancer. An estimated 220,800 […]

View full entry

Tags: adt, androgen deprivation therapy, endrocrine treatment, ET, News, Prostate Cancer, radiation therapy


May 17th, 2016

Chemotherapy After Prostatectomy Delays Cancer Progression in High-Risk Prostate Cancers

By

The use of chemotherapy following a radical prostatectomy delays the time to cancer progression among men with prostate cancer who are at a high risk of developing a recurrence.  These results were recently presented at the 2016 Annual Scientific Meeting of the American Urological Association (AUA). Over 200,000 men each year in the United States […]

View full entry

Tags: African American men, Chemotherapy, News, Prostate Cancer, radical prostatectomy, recurrence


April 25th, 2016

Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer

By

Among men with early prostate cancer, the risk of depression is increased with the use of androgen-deprivation therapy (ADT), particularly among men who are treated with ADT for 12 months or longer.  It is important for patients receiving ADT to speak with their healthcare providers if they experience any feelings of depression, as effective treatment […]

View full entry

Tags: adt, depression, Early Stage I-II (A-B) Prostate Cancer, News, Prostate Cancer, testosterone


March 14th, 2016

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers

By

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy raise their risk of getting other cancers by nearly 70 percent, according to the results of a new study. There is a well-documented association between exposure to radiation […]

View full entry

Tags: Bladder Cancer, bowel cancer, carcinogenesis, Colon Cancer, exposure, Hodgkin's Lymphoma, News, Prostate Cancer, radiation therapy, Rectal Cancer, secondary cancer


March 9th, 2016

Shorter Radiation Schedule Effective in Low-Risk Prostate Cancer

By

Men with low-grade prostate cancer have the same long-term outcomes when they are treated with a shorter radiation schedule, compared to those treated with a longer, conventional radiation schedule. These results were recently presented at the 2016 annual Genitourinary Cancers Symposium. Low-grade prostate cancer refers to cancer that has not spread to distant sites in […]

View full entry

Tags: clinical trial, hypofractionated, Prostate Cancer, radiation


February 22nd, 2016

Xtandi® Improves Survival in Advanced Prostate Cancer

By

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently published as rapid communication in the Journal of Clinical Oncology. Prostate cancer is the most frequently diagnosed cancer in men […]

View full entry

Tags: bicalutamide, casodex, Early Stage I-II (A-B) Prostate Cancer, enzalutamide, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi


February 2nd, 2016

Prostate Cancer: Year in Review

By

In 2015, the increased use of Oncotype DX prostate cancer test promoted changes in treatment received, resulting in greater recommendations and adoption of active surveillance. Also noteworthy is the research devoted to best standard of treatment for all stages of prostate cancer. CancerConnect News coverage of advances in the management of prostate cancer included the […]

View full entry

Tags: News, Prostate Cancer, review, update


November 5th, 2015

Shorter Course of Radiation as Effective as Longer Course in Low-Risk Prostate Cancer

By

A shorter course of hypofractionated radiation therapy, a treatment in which larger doses of radiation are delivered over a shorter time period than conventional radiation, appears as effective as longer courses for men with low-risk prostate cancer. These results were recently presented at the 57th annual meeting of the American Society for Therapeutic Radiation (ASTRO). […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, hypofractionated radiation therapy, low-risk, News, Prostate Cancer


November 4th, 2015

Combined Hormone and Radiation Therapy Superior to Radiation Alone for Prostate Cancer Recurring After Prostatectomy

By

The addition of two years of anti-androgen therapy (AAT) to radiation therapy reduces the risk of death caused by prostate cancer among men treated for a recurrence following a prostatectomy. Treatment for early prostate cancer often includes the surgical removal of the prostate (prostatectomy). Unfortunately, some patients will experience a cancer recurrence following surgery. Treatment […]

View full entry

Tags: anti-androgen therapy, ATT, clinical trial, News, Prostate Cancer, prostatectomy, radiation, recurrence, Refactory/Recurrent Prostate Cancer